Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ADD-Vantage, a two-part system that does not require clinicians to use needle and syringe to mix drug and solution
Subscribe to our email newsletter
Hospira has received FDA approval for a 500mg vial of azithromycin for injection, in the ADD-Vantage System. The anti-infective medication is a generic version of Pfizer’s Zithromax for injection.
ADD-Vantage is a two-part system that does not require clinicians to use a needle and syringe to mix the drug and the solution. This reduces the risk of accidental needlesticks, and can result in less waste due to stability and shelf-life factors, said the company.
Hospira’s specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in different dosages and formulations. Therapeutic areas include anesthesia, anti-infectives, analgesics, cardiovascular, oncology, and emergency. Hospira has approximately 25 generic drugs scheduled to launch around the world in 2009 and 2010.